ReviewMolecular diversity2025
An updated survey on the recent advancement of antimalarial molecules: synthetic methodologies and SAR studies.
Review in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rational Design of N-2-(7-Chloroquinolin-4-ylamino)ethyl Amides Active Against Chloroquine-Resistant Plasmodium falciparum.Archiv der Pharmazie · 2026Article
- From molecule to medicine: introducing emerging strategies to synthesize potent anticancer purine scaffolds.RSC advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An ongoing escalation in malaria cases is a critical global health issue and also a leading source of increased mortality rates. Infected mosquitos spread the Plasmodium parasite-based disease,. Recent advancements in antimalarial drug discovery have focused on developing novel molecules with unique mechanisms of action to combat this growing resistance. This review focuses on the latest findings in synthesizing hybrid antimalarial compounds, which combine different pharmacophores to enhance therapeutic efficacy, resulting in compounds that exhibit potent action against both resistant/sensitive strains of chloroquine, quinine, and artemisinin. Notably, the incorporation of diverse scaffolds such as 1,2,4-trioxanes, halogenated quinolines, pyrazoline, and sulfonamides has led to promising candidates that not only demonstrate high potency but also favorable pharmacokinetic profiles for drug development, the exploration of novel targets. This review highlights the progress (2019-2024) made in identifying and synthesizing hybrid antimalarial molecules while addressing existing challenges in the field.
Indexed as
Identifiers
40153157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.